STOCKWATCH: Gilead damned for doing the right thing
This article was originally published in Scrip
The last thing you need on a Friday afternoon is for one of your biotech holdings to open the trading session down by more than 7%. And as the company in question was the large capitalization and profitable antiviral specialist Gilead Sciences, I did wonder if a new global conflict rather than a Ukrainian ceasefire had just been announced. But in this case, the news that took Gilead's share price down was entirely of its own making and, even worse, the reaction was in response to Gilead's best of intentions.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.